Taken together, this suggests that increased tumor CD73 following MEKi might increase FcR‐mediated recruitment of CD45+CD3− cells, leading to the observed augmented effect of anti‐CD73 antibody combined with MEKi, while the effect of limiting adenosine might only partly contribute to the effect of TY/23 in our model. The gene discussed is PTPRC; the disease is neoplasm.